<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084249</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVE-IT2</org_study_id>
    <nct_id>NCT04084249</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer - Intervention Trial 2</brief_title>
  <acronym>IMPROVE-IT2</acronym>
  <official_title>Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer - Intervention Trial 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claus Lindbjerg Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided
      post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this
      study is that ctDNA guided post-operative surveillance combining ctDNA and radiological
      assessments could result in earlier detection of recurrent disease and identify more patients
      eligible for curative treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FCI</measure>
    <time_frame>5 years</time_frame>
    <description>Fraction of patients with relapse receiving intended curative resection or local treatment aiming at complete tumor destruction as defined at the relevant MDT conference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3yr-OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5yr-OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTCR</measure>
    <time_frame>3 years</time_frame>
    <description>Time to clinical recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTMR</measure>
    <time_frame>2 years</time_frame>
    <description>Time to molecular recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of Life by use of EORTC QLQ-C30, version 3.0. The QoL outcome measure is differences in QLQ-C30 score at 12, 24 and 36 months between the experimental and control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FCRI</measure>
    <time_frame>3 years</time_frame>
    <description>Fear of Cancer Recurrence Inventory. The FCRI outcome measure is differences in FCRI at 12, 24 and 36 months between the experimental and control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IES-C</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Events Scale Cancer. The IES-C outcome measure is differences in IES-C at 12, 24 and 36 months between the experimental and control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE</measure>
    <time_frame>5 years</time_frame>
    <description>Cost-effectiveness. QoL/Utility weights for the quality-adjusted life years parameter will be QLU-C10D based on EORTC QLQ-C30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <condition>ctDNA</condition>
  <condition>Gastro-Intestinal Disorder</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Disease</condition>
  <condition>Digestive System Neoplasm</condition>
  <condition>Colonic Diseases</condition>
  <condition>Colonic Neoplasms</condition>
  <condition>Colonic Cancer</condition>
  <condition>Rectal Diseases</condition>
  <condition>Rectal Neoplasms</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>ctDNA guided surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the FCRI questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Danish follow-up program</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ctDNA-analysis</intervention_name>
    <description>Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).</description>
    <arm_group_label>ctDNA guided surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensified Follow-up Schedule</intervention_name>
    <description>PET/CT-scans every 3. month</description>
    <arm_group_label>ctDNA guided surveillance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colon or rectal cancer, tumor stage III (pT1-4N1-2,cM0) or stage II high-risk
             (pT4N0,cM0 and pT3N0, cM0 with risk factors)

          -  Have received curative intend resection and be candidates for adjuvant chemotherapy

        Exclusion Criteria:

          -  Not treated with adjuvant chemotherapy

          -  Synchronous colorectal and non-colorectal cancer diagnosed per-operative (except skin
             cancer other than melanoma)

          -  Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within
             3 years from screening

          -  Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude),
             inability to return for subsequent visits) and/or otherwise considered by the
             Investigator to be unlikely to complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus L Andersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular Medicin, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus L Andersen, PhD</last_name>
    <phone>+45 78455319</phone>
    <email>cla@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaare A Gotschalck, PhD</last_name>
    <phone>+45 78423786</phone>
    <email>kaarsune@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Surgical Department, Randers Regional Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaare Andersson Gotschalck, MD, PhD</last_name>
      <phone_ext>+45</phone_ext>
      <email>kaarsune@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jesper Nors, MD</last_name>
      <phone>c</phone>
      <phone_ext>+45</phone_ext>
      <email>jenors@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Claus Lindbjerg Andersen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Colonic Diseases</mesh_term>
    <mesh_term>Rectal Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

